T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
American Airlines Group
AAL
$9.97B
| $15.5M | ﹤0.01% |
861,435
+6,229
| +0.7% | +$91.3K |
|
1002
Supernus Pharmaceuticals
SUPN
$2.74B
| $15.4M | ﹤0.01% |
513,004
+3,032
| +0.6% | +$106K |
|
1003
Symbotic
SYM
$5.43B
| $15.4M | ﹤0.01% |
+358,700
| New | +$11.8M |
|
|
AMAM
1004
DELISTED
Ambrx Biopharma Inc
AMAM
| $15.3M | ﹤0.01% |
929,317
+718,690
| +341% | +$9.04M |
|
1005
Restaurant Brands International
QSR
$26.7B
| $15.2M | ﹤0.01% |
196,274
-27,996
| -12% | -$2.02M |
|
1006
Cognex
CGNX
$10.4B
| $15.2M | ﹤0.01% |
270,903
-71,900
| -21% | -$3.72M |
|
1007
RXO
RXO
$3.85B
| $15.1M | ﹤0.01% |
668,127
+156,871
| +31% | +$3.16M |
|
1008
C.H. Robinson
CHRW
$17.5B
| $15M | ﹤0.01% |
159,193
-1,401,407
| -90% | -$135M |
|
1009
Suzano
SUZ
$9.84B
| $14.9M | ﹤0.01% |
+1,610,671
| New | +$14.1M |
|
|
CPRX
1010
DELISTED
Catalyst Pharmaceutical
CPRX
| $14.8M | ﹤0.01% |
1,101,390
+71,711
| +7% | +$1.03M |
|
1011
Universal Health Services
UHS
$10.1B
| $14.7M | ﹤0.01% |
93,226
-1,214
| -1% | -$169K |
|
1012
Healthpeak Properties
DOC
$14.3B
| $14.7M | ﹤0.01% |
730,155
+1,615
| +0.2% | +$33.5K |
|
|
CNTA
1013
DELISTED
Centessa Pharmaceuticals
CNTA
| $14.6M | ﹤0.01% |
2,363,211
+49,778
| +2% | +$236K |
|
1014
KBR
KBR
$4.81B
| $14.5M | ﹤0.01% |
223,515
+2,709
| +1% | +$162K |
|
1015
First American
FAF
$7.56B
| $14.4M | ﹤0.01% |
252,944
+1,020
| +0.4% | +$57.6K |
|
1016
Gibraltar Industries
ROCK
$1.45B
| $14.4M | ﹤0.01% |
228,075
+9,169
| +4% | +$496K |
|
1017
Voyager Therapeutics
VYGR
$198M
| $14.1M | ﹤0.01% |
1,229,981
+328,516
| +36% | +$3.4M |
|
|
JNPR
1018
DELISTED
Juniper Networks
JNPR
| $13.9M | ﹤0.01% |
443,694
-1,171
| -0.3% | -$36.1K |
|
1019
Warner Music
WMG
$13.3B
| $13.9M | ﹤0.01% |
532,184
-63,147
| -11% | -$1.75M |
|
1020
LCI Industries
LCII
$2.6B
| $13.8M | ﹤0.01% |
109,315
+2,003
| +2% | +$229K |
|
1021
Pentair
PNR
$10.7B
| $13.8M | ﹤0.01% |
213,460
| – | – |
|
1022
Vistra
VST
$49.1B
| $13.6M | ﹤0.01% |
518,397
-11,981
| -2% | -$293K |
|
1023
Tapestry
TPR
$25.9B
| $13.6M | ﹤0.01% |
317,728
-4,436
| -1% | -$185K |
|
1024
Qorvo
QRVO
$8.68B
| $13.5M | ﹤0.01% |
132,164
-271,952
| -67% | -$26.1M |
|
|
PYCR
1025
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $13.5M | ﹤0.01% |
569,695
-513
| -0.1% | -$12K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.